Current Report Filing (8-k)
May 10 2019 - 7:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 9, 2019
BioTime,
Inc.
(Exact
name of registrant as specified in charter)
California
|
|
1-12830
|
|
94-3127919
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1010
Atlantic Avenue, Suite 102
Alameda,
California
|
|
94501
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(510)
521-3390
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock
|
|
BTX
|
|
NYSE
American
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.08
|
Shareholder
Director Nominations.
|
To
the extent applicable, the information in Item 8.01 of this report is incorporated by reference into this Item 5.08.
Our
board of directors has established July 30, 2019 as the date of our 2019 annual meeting of shareholders (the “2019 Annual
Meeting”). This date is more than 60 days after the one-year anniversary of our 2018 annual meeting of shareholders, which
was held on May 1, 2018. The record date for shareholders eligible to receive notice of and vote at the 2019 Annual Meeting will
be June 10, 2019.
In
light of the foregoing, and in accordance with our amended and restated bylaws (the “Bylaws”), in order for shareholder
proposals and director nominations to be presented at the 2019 Annual Meeting, the proposing shareholder must notify us of such
intention by notice received at our principal executive offices not later than the close of business on May 20, 2019. Shareholder
proposals intended for inclusion in our proxy statement for the 2019 Annual Meeting pursuant to Rule 14a-8 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), must be received at our principal executive offices no later
than the close of business on May 20, 2019, which we believe is a reasonable time before we begin to print and mail proxy materials
for the 2019 Annual Meeting.
All
shareholder notices related to the 2019 Annual Meeting must conform to the applicable requirements of the Bylaws, the rules and
regulations promulgated under the Exchange Act and other applicable law. All such notices should be directed to: “BioTime,
Inc., 1010 Atlantic Avenue, Suite 102, Alameda, California 94501, Attention: Secretary.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIOTIME,
INC.
|
|
|
Date:
May 10, 2019
|
By:
|
/s/
Brian M. Culley
|
|
Name:
|
Brian
M. Culley
|
|
Title:
|
Chief
Executive Officer
|
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024